Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 157Carcinoma, Transitional Cell 56Non-Muscle Invasive Bladder Neoplasms 30Urethral Neoplasms 24Carcinoma, Renal Cell 23Neoplasms 19Kidney Neoplasms 15Pancreatic Neoplasms 14Ovarian Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Ureteral Neoplasms 11Urologic Neoplasms 9Colorectal Neoplasms 9Breast Neoplasms 9Lung Neoplasms 7Testicular Neoplasms 6Stomach Neoplasms 6Melanoma 6Sarcoma 5Urothelial Cancer 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Osteosarcoma 4Colonic Neoplasms 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

padeliporfin 5Nivolumab 5Ipilimumab 4Sunitinib 3Specimen Handling 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Abiraterone Acetate 3pembrolizumab 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2abiraterone 2Surveys and Questionnaires 2Radiation Dose Hypofractionation 2Pluvicto 2Paclitaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2vinflunine 1valrubicin 1tislelizumab 1temsirolimus 1sipuleucel-T 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Gemcitabine × Genitourinary × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Tianjin Medical University Second Hospital

Phase 2 Unknown
53 enrolled
Genitourinary

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT01599013 2015-12-08

JASINT1

Pierre Fabre Medicament

Phase 2 Completed
69 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡